Search for Clinical Trial Results
Malignant Mixed Mullerian Tumor - 25 Studies Found
Status | Study |
Completed |
Study Name: Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer Condition:
Date: 2004-01-09 Interventions:
|
Not yet recruiting |
Study Name: microRNA Profiles Identification in Adeno Carcinoma Prostate Cancer Condition: Prostate Carcinosarcoma Date: 2016-11-08 Interventions: Biological: High PSA levels |
Completed |
Study Name: Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors Condition:
|
No longer available |
Study Name: Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient Condition: Mullerian Mixed Tumor of Ovary Date: 2014-03-14 Interventions: Drug: ficlatuzumab humanized anti-hepatocyte growth factor (HGF) monoclonal antibody IV administration a |
Recruiting |
Study Name: Suitability of DCE-MRI for Detection of Vascular Changes After VBT Condition: Carcinoma of the Cervix, Carcinoma or Carcinosarcoma of the Uterus Date: 2013-11-11 Interventions: Radiation: Radiotherapy |
Recruiting |
Study Name: A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma Condition: Recurrent Endometrial Cancer Date: 2011-09-28 Interventions: Drug: Lapatinib and ixempra Ixabepilone 40 mg/m2 Lapatinib 250 mg |
Completed |
Study Name: Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer Condition:
|
Terminated |
Study Name: Topotecan in Treating Patients With Recurrent or Refractory Cancer of the Uterus Condition: Sarcoma Date: 2000-11-06 Interventions: Drug: topotecan hydrochloride |
Terminated |
Study Name: Malignant Mixed Mesodermal Tumor (MMMT) - Early Stage With Postoperative XRT/Chemotherapy Condition: Uterine Neoplasms Date: 2007-07-19 Interventions:
|
Recruiting |
Study Name: A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer Condition:
|